Market Cap 89.21B
Revenue (ttm) 48.30B
Net Income (ttm) -8.95B
EPS (ttm) N/A
PE Ratio 6.60
Forward PE 6.95
Profit Margin -18.53%
Debt to Equity Ratio 2.81
Volume 10,105,800
Avg Vol 14,111,561
Day's Range N/A - N/A
Shares Out 2.04B
Stochastic %K 34%
Beta 0.33
Analysts Sell
Price Target $52.68

Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 609 252 4621
Website: www.bms.com
Address:
Route 206 & Province Line Road, Princeton, United States
SuperGreenToday
SuperGreenToday Oct. 25 at 12:34 AM
$BMY Share Price: $43.84 Contract Selected: Nov 21, 2025 $45 Calls Buy Zone: $1.14 – $1.41 Target Zone: $2.08 – $2.54 Potential Upside: 72% ROI Time to Expiration: 27 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 24 at 11:47 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $BMY Current Share Price: $43.79 Contracts: $BMY December 18, 2026 $45 Calls Scale in: $4.41- $5.39 Scale out: $6.86-$8.82 Can Easily Capture: 60% ROI Blended DTE: 421 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Investment8844
Investment8844 Oct. 24 at 8:37 PM
$BMY Are we gonna see $50+ post ER ? Or we gonna see $36 finally again?
1 · Reply
Tuttaz
Tuttaz Oct. 24 at 8:01 PM
$BMY Should be 65+...
0 · Reply
stocksuck
stocksuck Oct. 24 at 7:18 PM
$BMY market new high and this down again what a piece of shit
0 · Reply
stocksuck
stocksuck Oct. 24 at 5:50 PM
$BMY I bought another 100 shares
0 · Reply
cb5000calls
cb5000calls Oct. 24 at 2:36 PM
$SLS This is a cornerstone IP filing — not a generic chemistry patent but a precision-medicine lock around ASXL1-mutated cancers. It secures Sellas’ differentiation in AML and MDS and supports expansion into solid tumors (colorectal, liver, breast). The inclusion of venetoclax + azacitidine combinations directly positions this as first-line-compatible with current AML standards. Expect this to be a core due-diligence element if any large pharma (e.g., $ABBV , $BMY , $PFE ) considers acquisition or co-development. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2025217597
2 · Reply
taxplanr
taxplanr Oct. 24 at 2:31 PM
Using the bodies own mitochondria to combat cancers chronic illnesses and autoimmune diseases is what emf device companies like $ECOR can do Not failed malignantRNA platforms with toxic chemo does $BNTX $MRNA $BMY
0 · Reply
stocksuck
stocksuck Oct. 24 at 1:35 PM
$BMY will stock ever go up
1 · Reply
Fredsavage911
Fredsavage911 Oct. 24 at 1:31 PM
0 · Reply
Latest News on BMY
The Play On Bristol-Myers Squibb

Oct 21, 2025, 11:27 AM EDT - 3 days ago

The Play On Bristol-Myers Squibb


My Top 3 Pharma Stocks

Oct 20, 2025, 11:38 AM EDT - 4 days ago

My Top 3 Pharma Stocks

AKRO ETNB LLY MRK NVO PFE SPY


Final Trade: WMT, AMZN, F, BMY

Oct 14, 2025, 6:20 PM EDT - 10 days ago

Final Trade: WMT, AMZN, F, BMY

AMZN WMT F


Bristol Myers Squibb: Value Emerges From Distress

Oct 11, 2025, 9:52 AM EDT - 13 days ago

Bristol Myers Squibb: Value Emerges From Distress


Bristol Myers buys Orbital Therapeutics for $1.5 billion

Oct 10, 2025, 7:05 AM EDT - 15 days ago

Bristol Myers buys Orbital Therapeutics for $1.5 billion


Bristol-Myers Squibb: Your Chance To Buy A Bargain 6% Yield

Oct 9, 2025, 12:00 PM EDT - 15 days ago

Bristol-Myers Squibb: Your Chance To Buy A Bargain 6% Yield


Final Trade: GDX, PFE, GFS, BMY

Oct 1, 2025, 6:32 PM EDT - 23 days ago

Final Trade: GDX, PFE, GFS, BMY

GDX GFS PFE


Bristol Myers to sell psoriasis drug at over 80% discount

Sep 25, 2025, 7:08 AM EDT - 4 weeks ago

Bristol Myers to sell psoriasis drug at over 80% discount


Buy Bristol Myers Squibb Stock At $45?

Sep 23, 2025, 6:55 AM EDT - 4 weeks ago

Buy Bristol Myers Squibb Stock At $45?


Bristol Myers Squibb Announces Dividend

Sep 17, 2025, 6:59 AM EDT - 5 weeks ago

Bristol Myers Squibb Announces Dividend


Bristol Myers to sell 60% stake in China joint venture

Sep 17, 2025, 12:04 AM EDT - 5 weeks ago

Bristol Myers to sell 60% stake in China joint venture


Bristol-Myers Squibb: Why Q2 Results Signal A Turning Point

Sep 8, 2025, 9:47 AM EDT - 6 weeks ago

Bristol-Myers Squibb: Why Q2 Results Signal A Turning Point


SuperGreenToday
SuperGreenToday Oct. 25 at 12:34 AM
$BMY Share Price: $43.84 Contract Selected: Nov 21, 2025 $45 Calls Buy Zone: $1.14 – $1.41 Target Zone: $2.08 – $2.54 Potential Upside: 72% ROI Time to Expiration: 27 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 24 at 11:47 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $BMY Current Share Price: $43.79 Contracts: $BMY December 18, 2026 $45 Calls Scale in: $4.41- $5.39 Scale out: $6.86-$8.82 Can Easily Capture: 60% ROI Blended DTE: 421 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Investment8844
Investment8844 Oct. 24 at 8:37 PM
$BMY Are we gonna see $50+ post ER ? Or we gonna see $36 finally again?
1 · Reply
Tuttaz
Tuttaz Oct. 24 at 8:01 PM
$BMY Should be 65+...
0 · Reply
stocksuck
stocksuck Oct. 24 at 7:18 PM
$BMY market new high and this down again what a piece of shit
0 · Reply
stocksuck
stocksuck Oct. 24 at 5:50 PM
$BMY I bought another 100 shares
0 · Reply
cb5000calls
cb5000calls Oct. 24 at 2:36 PM
$SLS This is a cornerstone IP filing — not a generic chemistry patent but a precision-medicine lock around ASXL1-mutated cancers. It secures Sellas’ differentiation in AML and MDS and supports expansion into solid tumors (colorectal, liver, breast). The inclusion of venetoclax + azacitidine combinations directly positions this as first-line-compatible with current AML standards. Expect this to be a core due-diligence element if any large pharma (e.g., $ABBV , $BMY , $PFE ) considers acquisition or co-development. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2025217597
2 · Reply
taxplanr
taxplanr Oct. 24 at 2:31 PM
Using the bodies own mitochondria to combat cancers chronic illnesses and autoimmune diseases is what emf device companies like $ECOR can do Not failed malignantRNA platforms with toxic chemo does $BNTX $MRNA $BMY
0 · Reply
stocksuck
stocksuck Oct. 24 at 1:35 PM
$BMY will stock ever go up
1 · Reply
Fredsavage911
Fredsavage911 Oct. 24 at 1:31 PM
0 · Reply
taxplanr
taxplanr Oct. 23 at 7:56 PM
$MRK $BMY EMF feeds and energizes Mitochondria not destroy it like malignantRNA
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 23 at 5:12 PM
Enter: $BMY NOV 14 2025 $45 CALLS Buy in Price: $1.76 - $1.85 Take Profit: $3.38 Stop Bleeding: $1.55 ROI Potential: 92% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
Midas8888
Midas8888 Oct. 23 at 3:16 PM
0 · Reply
framus_morrigan
framus_morrigan Oct. 23 at 2:51 PM
$BMY I hate this name ... >_<
1 · Reply
Midas8888
Midas8888 Oct. 23 at 2:39 PM
0 · Reply
Lincoln_Osiris
Lincoln_Osiris Oct. 23 at 2:32 PM
$BMY Best buy in the market for an easy 20-25% return in a year with capital appreciation, dividend, and OTM covered calls.
1 · Reply
Fredsavage911
Fredsavage911 Oct. 23 at 12:59 PM
$BMY Leronlimab (LL) a CCR5 inhibitor from Cytodyn (Cydy) was used in combination with checkpoint for hibitors in patients with metastatic triple negative breast cancer. LL increased PDL-1 allowing ICI to work in patients with previously cold tumors (tumors lacking PD-1/PDL-1). Below are initial results.
1 · Reply
biolover
biolover Oct. 23 at 12:08 PM
$TNGX $TNGX data out. Secures private funding for phase 3 Tolerability looks BIC Impressive RR in histology agnostic MTAP deleted tumors Overall RR 27%. ( $BMY reported 21%. ) BMS drug had some dose limiting toxicities of seizure and GI. Which is not seen with tango. There was mild liver enzyme, elevation with BMY which could complicate combinations and this is not seeing with Tango drug 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months with an objective response rate (ORR) of 25% – – Combination studies with RAS(ON) inhibitors ongoing, data anticipated 2026 – – 49% ORR and mPFS 9.1 months in histology agnostic cohort of multiple late line, difficult to treat cancers provide further evidence of strong activity –
0 · Reply
Quantumup
Quantumup Oct. 23 at 11:30 AM
JPMorgan⬆️the PT on $IDYA to $79 from $74, reiterated at an Overweight, and⬆️ darovasertib's probability of success (PoS) in the neoadjuvant setting to 70% from 60%—estimates peak sales of $500M in the U.S. alone—sees share upside into the mUM update. $IMCR $PFE $MRK $BMY
0 · Reply
Stonkadonkera
Stonkadonkera Oct. 23 at 3:10 AM
$SLS not selling til $BMY or $PFE open the vault that $SLS can back the truck up to.
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 23 at 12:30 AM
Enter: $BMY NOV 14 2025 $45 CALLS Buy in Price: $1.76 - $1.92 Take Profit: $3.91 Stop Bleeding: $1.55 ROI Potential: 122% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
taxplanr
taxplanr Oct. 22 at 9:43 PM
$BNTX same old story for malignantRNA platform $BMY
0 · Reply